Premium
Effects of kampo medicine keishikashakuyakuto on large intestine disease in mice
Author(s) -
Kimura Yoshiyuki
Publication year - 2019
Publication title -
traditional and kampo medicine
Language(s) - English
Resource type - Journals
ISSN - 2053-4515
DOI - 10.1002/tkm2.1232
Subject(s) - medicine , diarrhea , inflammatory bowel disease , gastroenterology , colitis , h&e stain , irritable bowel syndrome , immunology , disease , immunohistochemistry
ABSTRACT Aim The aim of this study was to examine the effects of keishikashakuyakuto (KST) on large intestine diarrhea and inflammation in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) mouse models. Methods This study examined the effects of KST on diarrhea and inflammatory bowel syndrome using 5‐hydroxytryptamine (5‐HT)‐induced diarrhea and 3% dextran sulfate sodium (DSS)‐treated colitis models. Results Keishikashakuyakuto (200 and/or 500 mg/kg) and ramosetron (5 μg/kg) prolonged the onset‐time of 5‐HT‐induced diarrhea in mice. KST and ramosetron prevented diarrhea and the stool score was decreased 60 min after 5‐HT treatment. The disease activity index in the 3% DSS‐treated mice was lower after oral KST than in mice given 3% DSS only. Furthermore, KST inhibited the decreases in red cells and platelets, and in hemoglobin and hematocrit that were observed in DSS‐treated mice. On colon histology using hematoxylin–eosin and direct fast scarlet staining, KST prevented the mucosa membrane ulceration and eosinophil infiltration of the mucosa membrane caused by DSS treatment. The increase in colonic monocyte chemoattractant protein 1, interleukin‐1β and tumor necrosis factor‐α in DSS‐treated mice was reduced by oral KST. Conclusion Keishikashakuyakuto may be effective for IBS and IBD.